Plasma Homocysteine Concentration, C677T MTHFR Genotype, and 844ins68bp CBS Genotype in Young Adults With Spontaneous Cervical Artery Dissection and Atherothrombotic Stroke

Alessandro Pezzini, MD; Elisabetta Del Zotto, MD; Silvana Archetti, PhD; Riccardo Negrini, MD; Paolo Bani, MD; Alberto Albertini, MD; Mario Grassi, PhD; Deodato Assanelli, MD; Roberto Gasparotti, MD; Luigi Amedeo Vignolo, MD; Mauro Magoni, MD; Alessandro Padovani, MD, PhD

Background and Purpose—The role of mild hyperhomocysteinemia as a risk factor for cerebral ischemia may depend on stroke subtype. To test this hypothesis, we undertook a prospective case-control study of a group of patients with spontaneous cervical artery dissection (sCAD), a group of patients with atherothrombotic stroke (non-CAD), and a group of control subjects.

Methods—Fasting total plasma homocysteine (tHcy) concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype were determined in 25 patients with sCAD, 31 patients 45 years of age with non-CAD ischemic stroke, and 36 control subjects. Biochemical data in the patient groups were obtained within the first 72 hours of stroke onset.

Results—Median tHcy levels were significantly higher in patients with sCAD (13.2 μmol/L; range, 7 to 32.8 μmol/L) compared with control subjects (8.9 μmol/L; range, 5 to 17.3 μmol/L; 95% CI, 1.05 to 1.52; P=0.006). Cases with tHcy concentration above the cutoff level of 12 μmol/L were significantly more represented in the group of patients with sCAD compared with control subjects (64% versus 13.9%; 95% CI, 2.25 to 44.23; P=0.003); a significant association between the MTHFR TT genotype and sCAD was also observed (36% versus 11.1%; 95% CI, 1.10 to 19.23; P=0.045). No significant difference in tHcy levels and in the prevalence of thermolabile MTHFR was found between patients with non-CAD ischemic stroke and control subjects and between patients with sCAD and non-CAD ischemic stroke. The distribution of the 844ins68bp CBS genotype and the prevalence of subjects carrying both the TT MTHFR and 844ins68bp CBS genotypes were not significantly different among the 3 groups.

Conclusions—Our results are consistent with the hypothesis that increased plasma homocysteine levels and the TT MTHFR genotype may represent risk factors for sCAD. In contrast, their role in atherothrombotic strokes remains a contentious issue. (Stroke. 2002;33:664-669.)

Key Words: cervical artery dissection ▪ cystathionine β-synthase ▪ homocysteine ▪ methylenetetrahydrofolate reductase

Cervical artery dissection (CAD) accounts for up to one fifth of ischemic strokes occurring in young and middle-aged patients.1 Despite the increasing clinical awareness and the development of noninvasive investigational tools such as ultrasound techniques and MRI, the pathogenesis of this condition remains unclear, and the potential role of common risk factors for vascular disease is still controversial. However, epidemiological observations suggest that some as-yet-recognized predisposing factors could be heritable2-4 and that CAD might be the result of coexisting genetic and environmental factors.

In the past decade, raised plasma total homocysteine (tHcy) level has emerged as a potential risk factor for the development of vascular disease.5,6 Mild hyperhomocysteinemia may result from both nutritional and genetic influences. The most common genetic defect associated with raised Hcy is the C-to-T substitution at nucleotide 677 in the coding region of the gene for methylenetetrahydrofolate reductase (MTHFR), which is associated with a thermolabile variant of the enzyme with about half-normal activity. Mutations in the cystathionine β-synthase (CBS) gene, the key enzyme in the trans-sulfuration of Hcy to cystathionine, may also be associated...
with altered Hcy metabolism and premature vascular disease.\(^7\)

Whether mild hyperhomocysteinemia can be a causative risk factor for ischemic stroke is still controversial. Most retrospective studies found higher mean Hcy levels in patients with arterial thrombosis,\(^8\)\(^,\)\(^9\) whereas results from prospective studies indicated smaller or no association. In particular, several findings indicate that Hcy concentrations are not significantly increased during the acute phase of stroke but rise after the event,\(^10\)\(^,\)\(^11\) thus prompting speculation that mild hyperhomocysteinemia does not predate ischemic stroke but could be the consequence of tissue damage as such. A possible limitation of most studies is that they have correlated Hcy concentrations with all kinds of strokes without considering the specific subtypes. In line with these observations, Gallai and coworkers\(^12\) recently suggested that mild hyperhomocysteinemia might represent a predisposing condition for spontaneous CAD (sCAD).

To test the hypothesis that raised Hcy concentration and its genetic determinants are associated with sCAD but not with ischemic stroke of different pathogenesis, we undertook a prospective case-control study of consecutive patients admitted to our department. Fasting levels of tHcy, genotyping for the C677T mutation of the MTHFR gene and for the 844ins68bp mutation of the CBS gene, were determined in a series of patients with sCAD and compared with those of a group of patients with atherothrombotic stroke (non-CAD) and with those of a group of control subjects.

**Subjects and Methods**

Consecutive patients admitted to our department between January 1997 and December 2000 were prospectively considered for participation. All subjects in whom clinical and/or duplex ultrasound examination with a reversed-phase column. The interassay and intra-assay variations were <7%. Hyperhomocysteinemia was defined as fasting plasma tHcy levels >10\(\mu\)mol/L.\(^19\) Folate and vitamin B\(_12\) concentrations were determined in heparin-anticoagulated whole blood by use of standard DNA extraction. Genotyping for the C677T mutation of the CBS gene was also performed, according to a standardized multiplex polymerase chain reaction method.\(^16\) Doppler ultrasonography with frequency spectral analysis and B-mode echotomography of the cervical arteries and transcranial Doppler ultrasonography were also performed in all patients on admission. Conventional angiography and/or MRA were used to investigate extracranial and intracranial vessels. Transthoracic and/or transesophageal echocardiography with intravenous injections of agitated saline with the patient at rest and during the Valsalva maneuver was performed to rule out cardiac sources of emboli.

On the basis of such investigations, patients were classified according to a classification based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria, accommodated and validated for the cause of stroke in the young.\(^17\)

In both sCAD and non-CAD ischemic stroke groups, only the subjects in whom clinical evaluation and collection of blood samples were performed within 72 hours from signs and/or symptoms onset were eligible for the study. Reference control subjects matched to the cases by age in 3-year bands and by ethnic and geographic origin were selected from the list of local general practitioners by random-digit dialing after exclusion of individuals with known history of vascular disease. The study was designed and carried out in accordance with the ethical principles established by the local Institutional Guidelines on Clinical Investigation. Written informed consent was provided by all study participants.

Demographic data (age, sex) and history of conventional vascular risk factors, including hypertension, diabetes mellitus, cigarette smoking, and hypercholesterolemia, were obtained from each subject. Hypertension was considered present if systolic blood pressure was >160 mm Hg and diastolic pressure was >95 mm Hg in 2 separate measurements after the acute phase or if the subject was under treatment with antihypertensive drugs before recruitment. The diagnosis of diabetes mellitus was established according to World Health Organization criteria.\(^18\) Cigarette smokers were categorized as current smokers or nonsmokers (the latter included former smokers who had quit smoking for at least 6 months before the study). Hypercholesterolemia was considered present if cholesterol serum levels were >220 mg/dL or if the subject was under treatment with cholesterol-lowering drugs.

In all subjects, we measured fasting plasma tHcy concentration, serum levels of cobalamin (vitamin B\(_12\)) and folate and carried out genetic analysis of the C677T mutation in the MTHFR gene and of the 844ins68bp mutation in the CBS gene.

**Biochemical and Genetic Analyses**

For determination of plasma tHcy levels, venous blood sampling took place in the early morning (before 7 AM) in subjects after overnight fasting. tHcy was measured photometrically after separation with a reversed-phase column. The interassay coefficients of variation for this assay were <7%. Hyperhomocysteinemia was defined as fasting plasma tHcy levels >12\(\mu\)mol/L.\(^19\) Folate and vitamin B\(_12\) concentrations were determined in heparinized plasma by routine hospital assays.

Genomic DNA was isolated from \(-20^\circ\)C frozen samples of EDTA-anticoagulated whole blood by use of standard DNA extraction. Genotyping for the CBS 844ins68bp was performed according to the method of Sebastiao and coworkers.\(^20\) MTHFR genotypes...
were determined according to the method of Froseth and coworkers21 using polymerase chain reaction amplification and restriction digestion with *HinI* to distinguish mutant from wild-type alleles.

**Statistical Analysis**

Data were analyzed with the SPSS (version 10.1) program. A value of *P*<0.05 on 2-sided tests was considered significant. A multinomial logistic regression model that included age, sex, hypertension, smoking status, hypercholesterolemia, B<sub>12</sub>, folate, 844ins68bp mutation in the CBS gene, *TT MTHFR* genotype, and tHcy was used to examine the effect of these variables in the prediction of sCAD or non-CAD ischemic strokes. A second model that included the categorical variable hyperhomocysteinemia instead of the continuous variable plasma tHcy was also performed. Finally, the effect of genotypes on the prediction of sCAD or non-CAD ischemic strokes was tested in a further multinomial logistic regression model that included age, sex, hypertension, smoking status, hypercholesterolemia, and *TT MTHFR* or 844ins68bp CBS genotype. The variables tHcy, B<sub>12</sub>, and folate were not considered genotype predictors and thus were not entered into this model. Diabetes mellitus was also not entered into the multiple regression equations because of the low frequency of this condition in the present series. Results are given as 95% CI.

**Study Group**

Thirty-eight patients with CAD were recruited. Thirteen were excluded from final analysis: 3 owing to traumatic damage of the arterial wall as a consequence of either car accident (n=2) or fight (n=1), 8 owing to late admission (after the first 72 hours from symptoms onset), and 2 because of an unwillingness to participate. Thus, a total number of 25 unrelated patients were included. Intravenous heparin was administered for 7 to 10 days and then changed to oral anticoagulant therapy in all patients admitted in the acute phase. Fasting blood samples were collected within 24 hours of symptoms onset in 12 patients (48%), within 48 hours in 6 (24%), and during the acute phase. Twenty-four hours later, the acute event was associated with upper respiratory tract infection in 2 patients and with wind instrument playing in 1 patient.

**Results**

Data on Hcy concentration are summarized in the Figure. The fasting median plasma tHcy levels were higher in patients with sCAD (13.2 μmol/L; range, 7 to 32.8 μmol/L) compared with control subjects (8.9 μmol/L; range, 5 to 17.3 μmol/L) and patients with non-CAD ischemic stroke (10.9 μmol/L; range, 6 to 30.2 μmol/L). There was a positive relationship between tHcy concentration and sCAD. In particular, a significant difference was found compared with control subjects (95% CI, 1.05 to 1.52; *P*=0.006). This difference remained significant (95% CI, 1.02 to 1.48; *P*=0.038) even after the exclusion of the sCAD cases with no evidence of structural ischemic cerebral lesions (median plasma tHcy concentration in the subgroup with cerebral infarction, 13.5 μmol/L; range, 7 to 22.7 μmol/L). In contrast, although there was a tendency toward a higher median concentration in patients with non-CAD ischemic stroke compared with control subjects, the difference was not statistically significant (95% CI, 0.95 to 1.35). No significant difference was found between the group of patients with sCAD and the group of patients with non-CAD ischemic stroke (95% CI, 0.80 to 1.56).

Similar results were obtained comparing the prevalence of subjects whose plasma tHcy levels were above the normal values in each group. A significant difference (95% CI, 2.25 to 44.23; *P*=0.003) was observed between the group of patients with sCAD (n=16 subjects with abnormal tHcy values; 64%) and the group of control subjects (n=5 subjects with abnormal tHcy values; 13.9%), whereas there was no significant difference between the group of patients with

### TABLE 1. General Characteristics of the Study Population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>sCAD (n=25)</th>
<th>Non-CAD Ischemic Stroke (n=31)</th>
<th>Control Subjects (n=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>42.3±11.2</td>
<td>39.9±4.2</td>
<td>40.9±9.9</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>15 (60)</td>
<td>20 (64.5)</td>
<td>23 (63.9)</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>10 (40)</td>
<td>13 (41.9)</td>
<td>11 (30.6)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>4 (16)</td>
<td>4 (12.9)</td>
<td>3 (8.3)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>1 (4)</td>
<td>2 (6.5)</td>
<td>0</td>
</tr>
<tr>
<td>Hypercholesterolemia, n (%)</td>
<td>5 (25)</td>
<td>6 (19.4)</td>
<td>7 (19.4)</td>
</tr>
</tbody>
</table>
non-CAD ischemic stroke (n=9 subjects with abnormal tHcy values; 29%) and the group of control subjects (95% CI, 0.50 to 8.77), as well as between the group of patients with sCAD and the group of patients with non-CAD ischemic stroke (95% CI, 0.36 to 63.27). None of the other variables that were entered into the multiple regression equation were significant risk factors for sCAD.

We next investigated the prevalence of the TT MTHFR genotype in each group. The homozygous TT transition was present in 9 of 25 patients (36%) with sCAD, in 4 of 31 patients (12.9%) with non-CAD ischemic stroke, and in 4 of 36 control subjects (11.1%; Table 2).

There was a significant association between the TT genotype and the group of patients with sCAD compared with control subjects (95% CI, 1.10 to 19.23; P=0.045). No significant difference in TT frequency was observed between the group of patients with non-CAD ischemic stroke and the group of control subjects (95% CI, 0.23 to 5.15) or between the group of patients with sCAD and the group of patients with non-CAD ischemic stroke (95% CI, 0.30 to 58.7).

As opposed to the TT MTHFR genotype, the frequency of the 844ins68bp CBS mutation (12% in the group of patients with sCAD, 13.9% in the group of controls, and 25.8% in the group of patients with non-CAD ischemic stroke) was not statistically different among the 3 groups after multiple regression analysis (P=0.411). Similarly, there was no difference in the frequency of subjects carrying the combination of both the 844ins68bp CBS mutation and the MTHFR TT genotype (1 in each group).

### Discussion
The main finding in the present study is the evidence that both high plasma levels of tHcy and the homozygous MTHFR TT genotype are strongly associated with sCAD. In contrast, neither fasting tHcy levels nor the frequency of the thermolabile form of MTHFR significantly differed between patients with non-CAD ischemic stroke and control subjects.

To the best of our knowledge, there have been only sparse reports and 1 prospective case-control study of the relationship between fasting tHcy and sCAD. The evidence derived from such study agrees with our results arguing for a strong relationship between high levels of tHcy and arterial dissection. However, that study failed to detect any association between genetic abnormalities in Hcy metabolism and risk of sCAD. No previous studies compared fasting tHcy level and its genetic determinants in stroke patients with primary vascular disorders of different pathogenesis, such as arterial dissection and atherothrombosis of large and small vessels. The raised concentrations of tHcy we found in sCAD patients immediately after the acute event are suggestive of a causal association, whereas, in agreement with the results of previous prospective studies, we observed no evidence of such a correlation in cases of stroke caused by a presumed atherothrombotic process. Taken together, these findings are consistent with the hypothesis that the role played by Hcy in the pathophysiology of cerebral ischemia may depend on the stroke subtypes and the specific underlying mechanism.

### Table 2. Distribution of the MTHFR Genotypes in the 3 Groups

<table>
<thead>
<tr>
<th>MTHFR genotype, % (n)</th>
<th>sCAD (n=25)</th>
<th>Non-CAD Ischemic Stroke (n=31)</th>
<th>Control Subjects (n=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TT</td>
<td>36% (9)</td>
<td>12.9% (4)</td>
<td>11.1% (4)</td>
</tr>
<tr>
<td>Tt</td>
<td>36% (9)</td>
<td>58.1% (18)</td>
<td>38.9% (14)</td>
</tr>
<tr>
<td>tt</td>
<td>28% (7)</td>
<td>29% (9)</td>
<td>50% (18)</td>
</tr>
<tr>
<td>T-t allele ratio</td>
<td>0.54:0.46</td>
<td>0.42:0.58</td>
<td>0.31:0.69</td>
</tr>
</tbody>
</table>
Although the exact process leading to sCAD remains elusive, a structural defect of the arterial wall is thought to represent a predisposing condition. Recently, Brandt and coworkers found irregular collagen fibrils and elastic fiber fragmentation in skin biopsies of the majority of subjects from a series of sCAD patients, providing further evidence of a plausible relationship between sCAD and generalized connective tissue disorders and supporting the hypothesis that potential defects in the extracellular matrix of the vessel wall may play a key role in the pathogenesis of arterial dissection. Indirect evidence of an underlying structural defect of the arterial wall is also suggested by the association of sCAD with other vascular disorders.

Several biological mechanisms might explain the association between increased levels of plasma tHcy and arterial dissection. Among these, a link between hyperhomocysteinemia and abnormalities in the elastic components of the arterial wall has been reported. In vitro studies demonstrate that high levels of plasma Hcy result in a decrease in the elastin content of the arterial wall as a direct or an indirect consequence of the Hcy-induced activation of metalloproteinases and serine elastases. This increased elastolytic activity may result in an opening and enlargement of fenestrae in the medial elastic laminae, leading to a premature fragmentation of the arterial elastic fibers and degradation of the extracellular matrix. Hcy has been shown to block aldehydeic groups in elastin, thereby inhibiting the cross-linking necessary to stabilize elastin. The cross-linking of collagen may also be impaired. Thus, Hcy may have an influence on the elastic properties of the arterial wall. These findings lead to the hypothesis that the toxic effect of Hcy might be more pronounced in the carotid artery and in the aorta with their many elastic laminas compared with the femoral and brachial arteries in which the muscular layer is thicker. The high frequency of carotid and aortic dissection compared with the low frequency in the femoral and brachial arteries is in line with these findings and indirectly strengthens the hypothesis of a link between increased levels of tHcy and sCAD.

A possible limitation of our study is inherent in the different therapeutic approaches to sCAD with respect to atherothrombotic strokes. However, there is no evidence that either antiplatelets or anticoagulant agents may influence plasma tHcy levels. Furthermore, we measured tHcy concentration in the very acute phase of the vascular event, which is likely to reduce the impact of this potential bias. This also allows us to refute the hypothesis that the raised concentrations of tHcy we observed might be the result of the increase in methylation reactions after tissue injury, which has been suggested to explain the high tHcy levels in patients sampled after the acute phase of stroke.

The association between sCAD and the homozygous MTHFR TT genotype is also worth mentioning. It has been reported that approximately 5% of patients with spontaneous arterial dissection have at least 1 family member who has had the same disorder. This finding suggests that the underlying structural defects of the arterial wall might be heritable in some cases. As to the 844ins68bp mutation in the CBS gene, it has been observed that the heterozygous state, combined with the thermolabile MTHFR, may increase the risk of venous and arterial occlusive disease. However, our findings do not support this hypothesis and a relationship between the 844ins68bp mutation in the CBS gene, alone or in combination with the thermolabile MTHFR, and sCAD seems unlikely.

In conclusion, our data suggest that Hcy may play a differential role in the pathogenesis of vascular disorders, according to the specific mechanism of vascular injury. In particular, increased concentration of plasma tHcy seems to represent a predisposing condition for sCAD, whereas its role in atherothrombotic damage remains a contentious issue. Taking into account the relatively small number of subjects in the present study, we cannot exclude that the lack of significant difference between patients with atherothrombotic stroke and control subjects may be the result of an underpowered comparison. Furthermore, our data point to a relationship between genetic abnormalities in Hcy metabolism and risk of sCAD and suggest a potential association with polymorphisms in other genes.

References


Plasma Homocysteine Concentration, C677T MTHFR Genotype, and 844ins68bp CBS Genotype in Young Adults With Spontaneous Cervical Artery Dissection and Atherothrombotic Stroke

Alessandro Pezzini, Elisabetta Del Zotto, Silvana Archetti, Riccardo Negrini, Paolo Bani, Alberto Albertini, Mario Grassi, Deodato Assanelli, Roberto Gasparotti, Luigi Amedeo Vignolo, Mauro Magoni and Alessandro Padovani

Stroke. 2002;33:664-669
doi: 10.1161/hs0302.103625

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/33/3/664

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/